Jane Estell

2.3k total citations
16 papers, 210 citations indexed

About

Jane Estell is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jane Estell has authored 16 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 6 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jane Estell's work include Multiple Myeloma Research and Treatments (9 papers), CAR-T cell therapy research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Jane Estell is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), CAR-T cell therapy research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Jane Estell collaborates with scholars based in Australia, United States and Spain. Jane Estell's co-authors include Wolney Barreto, María‐Victoria Mateos, Paolo Corradini, Ajay K. Nooka, Eva Medvedova, Xiang Qin, Andrew Spencer, Jordan M. Schecter, Himal Amin and Rachel Kobos and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jane Estell

16 papers receiving 203 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Estell Australia 7 171 130 120 27 27 16 210
Pia Sondergeld Germany 4 220 1.3× 139 1.1× 135 1.1× 40 1.5× 24 0.9× 4 252
Wolney Barreto Brazil 6 155 0.9× 125 1.0× 106 0.9× 47 1.7× 14 0.5× 10 194
Daniel Morillo Spain 9 152 0.9× 98 0.8× 141 1.2× 32 1.2× 66 2.4× 30 275
Katarina Uttervall Sweden 8 202 1.2× 122 0.9× 121 1.0× 31 1.1× 28 1.0× 25 229
Laura Moreno Spain 6 157 0.9× 95 0.7× 106 0.9× 33 1.2× 44 1.6× 6 220
Britta Besemer Germany 11 197 1.2× 147 1.1× 160 1.3× 23 0.9× 66 2.4× 37 286
Robin Carson United States 10 204 1.2× 138 1.1× 160 1.3× 36 1.3× 28 1.0× 33 258
Christine Greil Germany 9 181 1.1× 176 1.4× 130 1.1× 18 0.7× 11 0.4× 24 295
Francesca Bonello Italy 9 143 0.8× 103 0.8× 105 0.9× 22 0.8× 28 1.0× 18 181
Albert Oriol Rocafiguera Spain 11 240 1.4× 172 1.3× 173 1.4× 12 0.4× 56 2.1× 26 284

Countries citing papers authored by Jane Estell

Since Specialization
Citations

This map shows the geographic impact of Jane Estell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Estell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Estell more than expected).

Fields of papers citing papers by Jane Estell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Estell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Estell. The network helps show where Jane Estell may publish in the future.

Co-authorship network of co-authors of Jane Estell

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Estell. A scholar is included among the top collaborators of Jane Estell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Estell. Jane Estell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Plesner, Torben, Simon J. Harrison, Hang Quach, et al.. (2023). Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma. SHILAP Revista de lepidopterología. 5(1). 43–51. 16 indexed citations
2.
3.
Kalff, Anna, Tiffany Khong, P. Joy Ho, et al.. (2021). Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica. 107(1). 321–325. 1 indexed citations
4.
5.
Plesner, Torben, Simon J. Harrison, Hang Quach, et al.. (2021). A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 138(Supplement 1). 2755–2755. 10 indexed citations
6.
7.
Mateos, María‐Victoria, Pieter Sonneveld, Vânia Hungria, et al.. (2019). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma Myeloma & Leukemia. 20(8). 509–518. 93 indexed citations
8.
Weisel, Katja, Pieter Sonneveld, María‐Victoria Mateos, et al.. (2019). Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor. Blood. 134(Supplement_1). 3192–3192. 26 indexed citations
9.
Mateos, María‐Victoria, Pieter Sonneveld, Vânia Hungria, et al.. (2018). Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor. Blood. 132(Supplement 1). 3270–3270. 8 indexed citations
10.
11.
Mateos, María‐Victoria, Jane Estell, Wolney Barreto, et al.. (2016). Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor. Blood. 128(22). 1150–1150. 28 indexed citations
12.
Bachy, Emmanuel, Jane Estell, Réda Bouabdallah, et al.. (2016). Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. American Journal of Hematology. 91(4). 410–415. 6 indexed citations
13.
Estell, Jane, et al.. (2014). A Novel Case of Symptomatic BK Viraemia in a Patient Undergoing Treatment for Hodgkin Lymphoma. SHILAP Revista de lepidopterología. 2014. 1–4. 1 indexed citations
14.
15.
Trotman, Judith, Yiu Lam Kwan, Campbell Tiley, et al.. (2008). Consensus guidelines for ‘rainy day’ autologous stem cell harvests in New South Wales. Internal Medicine Journal. 38(4). 229–234. 1 indexed citations
16.
Favaloro, Emmanuel J., Scott Mead, Anne T. Collins, et al.. (2008). Differential identification of PT‐VWD from type 2B VWD and GP1BA nomenclature issues response to Othman. British Journal of Haematology. 142(2). 314–315. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pia Sondergeld Breakdown of academic impact, for papers by Wolney Barreto Breakdown of academic impact, for papers by Daniel Morillo Breakdown of academic impact, for papers by Katarina Uttervall Breakdown of academic impact, for papers by Laura Moreno Breakdown of academic impact, for papers by Britta Besemer Breakdown of academic impact, for papers by Robin Carson Breakdown of academic impact, for papers by Christine Greil Breakdown of academic impact, for papers by Francesca Bonello Breakdown of academic impact, for papers by Albert Oriol Rocafiguera
Rankless by CCL
2026